The goal of this study is to determine the efficacy of the study drug olutasidenib to treat
newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring
an IDH1 mutation.
The main question the study aims to answer is whether the combination of olutasidenib and
temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.